A pilot study of Tideglusib treatment in AD showed a positive trend in cognition without significance ( 172 ), but a phase II clinical trial in AD did not show clinical benefit ( 173 ).
1
—
—
A pilot study of Tideglusib treatment in AD showed a positive trend in cognition without significance ( 172 ), but a phase II clinical trial in AD did not show clinical benefit ( 173 ).